MedPacto

MedPacto is a genome-based drug discovery and clinical-stage biotechnology company that is pursuing the development of first-in-class therapies to bring new hope to patients suffering from the most challenging diseases such as cancer. The leading drug candidate is Vactosertib, an orally bioavailable small-molecule inhibitor of the TGF- type I receptor (TRI) currently in phaseII clinical trials with global pharmaceutical companies such as Merck and AstraZeneca. Vactosertib inhibits transforming growth factor-beta (TGF-) pathway signaling, which is known to promote the metastasis and proliferation of cancer cells by modulating the tumor microenvironment. Vactosertib plays a synergistic role in improving the response to various therapies by inhibiting immune-suppressive TGF- activity and suppressing the resistance mechanism of cancer stem cells. MedPacto is currently conducting combination trials with Vactosertib targeting several cancer indications including colorectal cancer, pan...